Clinical Trial

Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

Completed
View on ClinicalTrials.gov →
Summary
This is a retrospective, observational study of treatment patterns and clinical outcomes in Australian EGFRm advanced and metastatic non-small cell lung cancer patients treated with first-line osimertinib or second-line osimertinib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-01; most recent amendment 2026-06-03.
Status change: Recruiting → Completed 2026-01-19
Trial Details
NCT Number NCT07213076
Lead Sponsor AstraZeneca
Collaborators: Peter MacCallum Cancer Centre, Australia
Conditions Non-small Cell Lung Cancer
Enrollment 350 participants
Start Date 2025-07-04
Primary Completion 2025-11-10 (estimated)
Study Completion 2025-11-10 (estimated)
Updated on ClinicalTrials.gov 2026-06-04